Reduced in vitro clot lysis and release of more active platelet PAI-1 in polycythemia vera and essential thrombocythemia

被引:27
作者
Pósán, E [1 ]
Ujj, G [1 ]
Kiss, A [1 ]
Telek, B [1 ]
Rák, K [1 ]
Udvardy, M [1 ]
机构
[1] Debrecen Univ Med, Sch Med, Dept Med 2, H-4012 Debrecen, Hungary
关键词
fibrinolysis; platelet-rich thrombus; polycythemia vera; essential thrombocythemia;
D O I
10.1016/S0049-3848(98)00005-X
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Because platelets interact with fibrinolysis in a complex manner, it can be expected that with abnormal platelet numbers and quality this interference can be even more profound. The aim of this work was to study the lysis-resistance of platelet-rich clots in diseases with high platelet counts: polycythemia vera (PV), essential thrombocythemia (ET) and to make comparison with polyglobulia (PG), Platelet-rich plasma (PRP) and platelet-poor plasma (PPP) were analyzed by an in vitro clot lysis test. Plasminogen activator inhibitor-1 (PAI-1) activity was measured in plasma and in the supernatants of the washed and gel-filtered platelets after activation by thrombin. The lysis showed decreased speed of PPP-clots in PV and ET. This phenomenon was even more marked in PRP-clots from PV and ET, but further increased lysis resistance after retraction was not observed in PV and ET, most likely due to abnormal platelet functions. Our results suggest that the fibrinolytic activity is reduced in PV and ET, and may play a role both in the increased aptitude for venous thrombosis and in the arterial complications. These are partly caused by higher plasmatic PAI-1 activity as well as by more active platelet PAI-1. The PAI-1 activity was significantly higher in the supernatants of the washed and gel-filtered platelets of PV after activation by thrombin compared with controls. Other factors might have influenced the reduced fibrinolysis. (C) 1998 Elsevier Science Ltd.
引用
收藏
页码:51 / 56
页数:6
相关论文
共 22 条
[11]  
MAEDA NY, 1990, BRAZ J MED BIOL RES, V23, P251
[12]   PLASMINOGEN INTERACTS WITH HUMAN-PLATELETS THROUGH 2 DISTINCT MECHANISMS [J].
MILES, LA ;
GINSBERG, MH ;
WHITE, JG ;
PLOW, EF .
JOURNAL OF CLINICAL INVESTIGATION, 1986, 77 (06) :2001-2009
[13]  
ORLANDI E, 1989, HAEMATOLOGICA, V74, P45
[14]  
SCHAFER AI, 1984, BLOOD, V64, P1
[15]   THE PHYSIOLOGICAL-ASPECTS OF FIBRINOLYSIS [J].
TAKADA, A ;
TAKADA, Y ;
URANO, T .
THROMBOSIS RESEARCH, 1994, 76 (01) :1-31
[16]   PROFILE OF BLOOD-COAGULATION AND FIBRINOLYSIS IN CHRONIC MYELOPROLIFERATIVE DISORDERS [J].
TAKAHASHI, H ;
HATTORI, A ;
SHIBATA, A .
TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 1982, 138 (01) :71-80
[17]   ATTENUATION OF THROMBOLYSIS BY RELEASE OF PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1 FROM PLATELETS [J].
TORRBROWN, SR ;
SOBEL, BE .
THROMBOSIS RESEARCH, 1993, 72 (05) :413-421
[18]   ALTERED LYSIS RESISTANCE OF PLATELET-RICH CLOTS IN PATIENTS WITH INSULIN-DEPENDENT DIABETES-MELLITUS [J].
UDVARDY, M ;
POSAN, E ;
HARSFALVI, J .
THROMBOSIS RESEARCH, 1995, 79 (01) :57-63
[19]   INCIDENCE AND CLINICAL RISK-FACTORS FOR BLEEDING AND THROMBOTIC COMPLICATIONS IN MYELOPROLIFERATIVE DISORDERS - A RETROSPECTIVE ANALYSIS OF 260 PATIENTS [J].
WEHMEIER, A ;
DAUM, I ;
JAMIN, H ;
SCHNEIDER, W .
ANNALS OF HEMATOLOGY, 1991, 63 (02) :101-106
[20]  
WEHMEIER A, 1989, HAEMOSTASIS, V19, P251